- Conditions
- Memory Disorders, Alzheimer's Disease
- Interventions
- Not listed
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 44
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Alzheimer Disease
- Interventions
- 18-F-Flortaucipir
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 60 Years and older · Female only
- Enrollment
- 614 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2030
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Alzheimer Disease
- Interventions
- F 18 T807 Flortaucipir
- Drug
- Lead sponsor
- Tammie L. S. Benzinger, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Cortico Basal Degeneration, Corticobasal Syndrome, Corticobasal Syndrome(CBS), Corticobasal Degeneration, Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS)
- Interventions
- C-11 ER176 Radiotracer, C-11 PiB, AV1451 Tau
- Diagnostic Test
- Lead sponsor
- Jennifer Whitwell
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Depression, Drive
- Interventions
- F 18 AV-1451 (Flortaucipir), [11C]-Pittsburgh Compound B ([11C]PiB)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 150 participants
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Alzheimer Disease, Dementia
- Interventions
- 11C-ER176, [F-18]MK-6240, Florbetaben, Magnetic Resonance Imaging
- Drug · Other
- Lead sponsor
- Jose Gutierrez, MD, MPH
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 238 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA), Alzheimer Disease, Alzheimer Disease, Early Onset, Amnestic Disorder, Amnestic Symptoms, Amnestic Mild Cognitive Disorder
- Interventions
- F-18 AV 1451, C-11 PiB
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Alzheimer Disease
- Interventions
- Flortaucipir F18, Brain PET Scan, Whole body PET scan, Florbetapir F 18, Brain MRI
- Drug · Procedure
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 2
- States / cities
- Cypress, California • Newport Beach, California
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia
- Interventions
- Clinical tau PET, Clinical amyloid test, Research blood collection, Cognitive assessments
- Diagnostic Test · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 1,800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Mild Cognitive Impairment, Healthy Aging
- Interventions
- Personalized DAT Risk Disclosure Protocol
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- Flortaucipir, Florbetaben, Fluorodeoxyglucose
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 40 Years to 64 Years
- Enrollment
- 850 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 18
- States / cities
- Sun City, Arizona • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
- Interventions
- Biomarker Data Collection
- Other
- Lead sponsor
- GAP Innovations, PBC
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 1,002 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 16
- States / cities
- Aventura, Florida • Coral Gables, Florida • Lady Lake, Florida + 13 more
- Conditions
- Alzheimer Dementia, Posttraumatic Stress Disorder, Traumatic Brain Injury
- Interventions
- MRI, PET, 18F-Florbetapir, Radioligand 18F-AV-1451
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Alzheimer Disease
- Interventions
- Transcranial Alternating Current Stimulation (tACS)
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer Disease, Cognitive Decline
- Interventions
- [18F]AV-1451, Positron Emission Tomography
- Drug · Procedure
- Lead sponsor
- Neil M Rofsky, MD, MHA
- Other
- Eligibility
- 38 Years to 96 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Dementia
- Interventions
- Neuraceq, Amyvid, Tauvid, MK-6240, NAV4694, PI-2620
- Radiation
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 1,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 46 more
- Conditions
- Down Syndrome, Alzheimer's Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 45 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Mild Cognitive Impairment
- Interventions
- Lithium Carbonate, Placebo oral capsule
- Drug
- Lead sponsor
- Ariel Gildengers, MD
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Alzheimer Disease
- Interventions
- Amyloid and Tau PET
- Drug
- Lead sponsor
- Banner Health
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Alzheimer Disease
- Interventions
- 18F-Flortaucipir radiopharmaceutical, 18F-MK-6240 radiopharmaceutical, Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol)
- Drug
- Lead sponsor
- Tharick Pascoal
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 822 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Berkeley, California • San Francisco, California • Rochester, Minnesota + 4 more
- Conditions
- Mild Cognitive Impairment, Dementia; Alzheimer's Type (Etiology)
- Interventions
- PET Biomarker Disclosure
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE), Progressive Supranuclear Palsy (PSP), Frontal Temporal Dementia (FTD), Pick's Disease, Tauopathies
- Interventions
- [18F]T807 ([18F]MNI-777)
- Drug
- Lead sponsor
- Molecular NeuroImaging
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Concussion, Brain
- Interventions
- [11C] PiB, [18F] PBR111, [18F] Flortaucipir
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 50 Years to 70 Years · Male only
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2028
- U.S. locations
- 3
- States / cities
- Waltham, Massachusetts • Chapel Hill, North Carolina • Milwaukee, Wisconsin
- Conditions
- Traumatic Brain Injury
- Interventions
- Cognitive/Neuropsychological Testing, Vestibular/Ocular-Motor Testing, Sleep Evaluation, MRI, High-Resolution, Health & Physical Exam, Physical Function, Blood Testing and Biomarker Analysis, Applanation Tonometry, PET brain imaging, [C-11]6-OH-BTA-1, [F-18]AV-1451
- Diagnostic Test · Drug
- Lead sponsor
- David Okonkwo, MD, PhD
- Other
- Eligibility
- 29 Years to 59 Years · Male only
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania